Neogenomics Inc balance sheet

At the end of fiscal 2025, Neogenomics Inc had total assets of $1.36bn, total liabilities of $523m and shareholders' equity of $837m. It held $160m in cash against $345m of debt.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Neogenomics Inc: balance sheet, annual
Fiscal year	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMSept 2026
Cash and equivalents	13	13	10	173	229	317	263	342	367	160	139
Receivables	56	60	77	94	107	112	120	131	151	159	213
Inventory	6	7	9	14	30	23	24	24	27	29	26
Total current assets	79	86	104	291	449	682	605	597	596	376	410
Goodwill	147	147	198	199	211	527	523	523	523	524	524
Total assets	337	344	505	710	988	1,870	1,740	1,681	1,638	1,360	1,377
Accounts payable	17	10	18	20	25	18	21	20	22	23	33
Deferred revenue (current)	—	1	1	2	4	5	8	2	0	1	0
Total current liabilities	38	36	61	64	73	87	90	96	301	88	116
Short-term debt	4	4	8	5	0	—	—	—	201	0	—
Long-term debt	92	91	93	95	169	533	535	538	340	342	375
Total debt	109	108	114	105	172	534	535	538	546	345	375
Total liabilities	151	140	185	202	294	762	742	740	736	523	576
Shareholders' equity	162	172	320	507	694	1,108	998	942	902	837	801
Non-controlling interests and other (assets − liabilities − equity)	24	33	—	—	—	—	—	—	—	—	—
Shares outstanding	79m	80m	94m	105m	112m	124m	127m	127m	128m	129m	129m

US$ millions unless shown otherwise. Fiscal quarters.

Neogenomics Inc: balance sheet, quarterly
Quarter	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026	2026 Q3Sept 2026
Receivables	151	151	153	155	159	167	175	213
Inventory	27	30	34	28	29	30	27	26
Total current assets	596	574	393	382	376	374	381	410
Goodwill	523	523	524	524	524	524	524	524
Total assets	1,638	1,601	1,394	1,375	1,360	1,347	1,352	1,377
Accounts payable	22	16	27	23	23	26	21	33
Deferred revenue (current)	0	1	1	2	1	1	0	0
Total current liabilities	301	280	100	98	88	85	106	116
Short-term debt	201	—	—	—	0	—	—	—
Long-term debt	340	—	—	—	342	—	374	375
Total debt	541	—	—	—	342	—	374	375
Total liabilities	736	713	540	536	523	518	567	576
Shareholders' equity	902	888	854	838	837	829	786	801
Shares outstanding	128m	128m	129m	129m	129m	130m	128m	129m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: NEO vs RGEN NEO vs TXG AZTA vs NEO NEO vs TECH

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Neogenomics Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Neogenomics Inc.